questionsmedicales.fr
Facteurs biologiques
Antigènes
Antigènes de surface
Molécules d'adhérence cellulaire
Lectine-2 de type Ig liant l'acide sialique
Lectine-2 de type Ig liant l'acide sialique : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Siglec-2
Dysfonction immunitaire
Immunohistochimie
Lectines
Cytométrie en flux
Siglec-2
Symptômes
5
Infections
Réactions inflammatoires
Fatigue
Réponse immunitaire
Douleurs articulaires
Inflammation
Allergies
Réponses inflammatoires
Éruptions cutanées
Inflammation
Prévention
5
Stress
Fonction immunitaire
Vaccinations
Réponse immunitaire
Exercice
Fonction immunitaire
Traitements
5
Thérapies biologiques
Anticorps monoclonaux
Anti-inflammatoires
Inflammation
Essais cliniques
Siglec-2
Thérapie génique
Siglec-2
Complications
5
Infections graves
Maladies auto-immunes
Maladies cardiovasculaires
Inflammation chronique
Maladies neurologiques
Siglec-2
Qualité de vie
Santé mentale
Facteurs de risque
5
Tabagisme
Fonction immunitaire
Obésité
Inflammation chronique
Diabète
Réponse immunitaire
Manque de sommeil
Fonction immunitaire
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Lectine-2 de type Ig liant l'acide sialique : Questions médicales les plus fréquentes",
"headline": "Lectine-2 de type Ig liant l'acide sialique : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Lectine-2 de type Ig liant l'acide sialique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-26",
"dateModified": "2025-02-20",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Lectine-2 de type Ig liant l'acide sialique"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Molécules d'adhérence cellulaire",
"url": "https://questionsmedicales.fr/mesh/D015815",
"about": {
"@type": "MedicalCondition",
"name": "Molécules d'adhérence cellulaire",
"code": {
"@type": "MedicalCode",
"code": "D015815",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.050.301.350"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Lectine-2 de type Ig liant l'acide sialique",
"alternateName": "Sialic Acid Binding Ig-like Lectin 2",
"code": {
"@type": "MedicalCode",
"code": "D051918",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Ken Kitajima",
"url": "https://questionsmedicales.fr/author/Ken%20Kitajima",
"affiliation": {
"@type": "Organization",
"name": "Biocience and Biotechnology Center, Nagoya University, Nagoya, 464-8601, Japan."
}
},
{
"@type": "Person",
"name": "Chihiro Sato",
"url": "https://questionsmedicales.fr/author/Chihiro%20Sato",
"affiliation": {
"@type": "Organization",
"name": "Biocience and Biotechnology Center, Nagoya University, Nagoya, 464-8601, Japan. chi@agr.nagoya-u.ac.jp."
}
},
{
"@type": "Person",
"name": "Thomas Haselhorst",
"url": "https://questionsmedicales.fr/author/Thomas%20Haselhorst",
"affiliation": {
"@type": "Organization",
"name": "Institute for Glycomics, Griffith University, Gold Coast, Queensland, Australia."
}
},
{
"@type": "Person",
"name": "Dinglong Yang",
"url": "https://questionsmedicales.fr/author/Dinglong%20Yang",
"affiliation": {
"@type": "Organization",
"name": "Muping Coastal Environment Research Station, Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai, 264003, PR China; Center for Ocean Mega-science, Chinese Academy of Sciences, Qingdao, Shandong, 266071, PR China. Electronic address: dlyang@yic.ac.cn."
}
},
{
"@type": "Person",
"name": "Takeo Tatsuta",
"url": "https://questionsmedicales.fr/author/Takeo%20Tatsuta",
"affiliation": {
"@type": "Organization",
"name": "Division of Cell Recognition Study, Institute of Molecular Biomembrane and Glycobiology, Tohoku Medical and Pharmaceutical University."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Impact of delivery time factor on treatment time and plan quality in tomotherapy.",
"datePublished": "2023-07-27",
"url": "https://questionsmedicales.fr/article/37500671",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-39047-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Background factors determining the time to intraocular lens dislocation.",
"datePublished": "2024-06-21",
"url": "https://questionsmedicales.fr/article/38904711",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10792-024-03166-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Bayesian Temporal Factorization for Multidimensional Time Series Prediction.",
"datePublished": "2022-08-04",
"url": "https://questionsmedicales.fr/article/33729926",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1109/TPAMI.2021.3066551"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Hearing rehabilitation in postmeningitis deafness in the context of the time factor].",
"datePublished": "2023-05-14",
"url": "https://questionsmedicales.fr/article/37182197",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1556/650.2023.32760"
}
},
{
"@type": "ScholarlyArticle",
"name": "Running-style modulation: Effects of stance-time and flight-time instructions on duty factor and cadence.",
"datePublished": "2022-10-07",
"url": "https://questionsmedicales.fr/article/36242910",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.gaitpost.2022.10.002"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Antigènes",
"item": "https://questionsmedicales.fr/mesh/D000941"
},
{
"@type": "ListItem",
"position": 4,
"name": "Antigènes de surface",
"item": "https://questionsmedicales.fr/mesh/D000954"
},
{
"@type": "ListItem",
"position": 5,
"name": "Molécules d'adhérence cellulaire",
"item": "https://questionsmedicales.fr/mesh/D015815"
},
{
"@type": "ListItem",
"position": 6,
"name": "Lectine-2 de type Ig liant l'acide sialique",
"item": "https://questionsmedicales.fr/mesh/D051918"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Lectine-2 de type Ig liant l'acide sialique - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Lectine-2 de type Ig liant l'acide sialique",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Lectine-2 de type Ig liant l'acide sialique",
"description": "Comment diagnostiquer une dysfonction de Siglec-2 ?\nQuels tests sont utilisés pour évaluer Siglec-2 ?\nY a-t-il des biomarqueurs associés à Siglec-2 ?\nQuels symptômes peuvent indiquer un problème avec Siglec-2 ?\nComment évaluer l'expression de Siglec-2 ?",
"url": "https://questionsmedicales.fr/mesh/D051918?mesh_terms=Time+Factors#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Lectine-2 de type Ig liant l'acide sialique",
"description": "Quels symptômes sont liés à une altération de Siglec-2 ?\nLa fatigue est-elle un symptôme associé à Siglec-2 ?\nDes douleurs articulaires peuvent-elles être liées à Siglec-2 ?\nLes allergies sont-elles influencées par Siglec-2 ?\nY a-t-il des signes cutanés associés à Siglec-2 ?",
"url": "https://questionsmedicales.fr/mesh/D051918?mesh_terms=Time+Factors#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Lectine-2 de type Ig liant l'acide sialique",
"description": "Comment prévenir les dysfonctionnements de Siglec-2 ?\nL'alimentation influence-t-elle Siglec-2 ?\nLe stress affecte-t-il Siglec-2 ?\nLes vaccinations aident-elles Siglec-2 ?\nY a-t-il des exercices bénéfiques pour Siglec-2 ?",
"url": "https://questionsmedicales.fr/mesh/D051918?mesh_terms=Time+Factors#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Lectine-2 de type Ig liant l'acide sialique",
"description": "Quels traitements ciblent Siglec-2 ?\nLes anti-inflammatoires aident-ils avec Siglec-2 ?\nY a-t-il des traitements expérimentaux pour Siglec-2 ?\nComment la thérapie génique peut-elle aider Siglec-2 ?\nLes probiotiques peuvent-ils influencer Siglec-2 ?",
"url": "https://questionsmedicales.fr/mesh/D051918?mesh_terms=Time+Factors#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Lectine-2 de type Ig liant l'acide sialique",
"description": "Quelles complications peuvent survenir avec Siglec-2 ?\nSiglec-2 est-il lié à des cancers ?\nLes maladies cardiovasculaires sont-elles liées à Siglec-2 ?\nY a-t-il des risques neurologiques associés à Siglec-2 ?\nComment les complications de Siglec-2 affectent-elles la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D051918?mesh_terms=Time+Factors#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Lectine-2 de type Ig liant l'acide sialique",
"description": "Quels facteurs de risque influencent Siglec-2 ?\nLe tabagisme affecte-t-il Siglec-2 ?\nL'obésité est-elle un facteur de risque pour Siglec-2 ?\nLe diabète influence-t-il Siglec-2 ?\nLe manque de sommeil affecte-t-il Siglec-2 ?",
"url": "https://questionsmedicales.fr/mesh/D051918?mesh_terms=Time+Factors#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction de Siglec-2 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des analyses de cellules immunitaires peuvent être effectués."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer Siglec-2 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'immunohistochimie et les tests de liaison des lectines sont courants."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés à Siglec-2 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux anormaux de Siglec-2 peuvent servir de biomarqueurs dans certaines maladies."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec Siglec-2 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections récurrentes ou une inflammation excessive peuvent être des signes."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'expression de Siglec-2 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'analyse par cytométrie en flux peut quantifier l'expression de Siglec-2."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une altération de Siglec-2 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des infections fréquentes et des réactions inflammatoires."
}
},
{
"@type": "Question",
"name": "La fatigue est-elle un symptôme associé à Siglec-2 ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fatigue peut survenir en raison d'une réponse immunitaire altérée."
}
},
{
"@type": "Question",
"name": "Des douleurs articulaires peuvent-elles être liées à Siglec-2 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une inflammation excessive due à Siglec-2 peut provoquer des douleurs articulaires."
}
},
{
"@type": "Question",
"name": "Les allergies sont-elles influencées par Siglec-2 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, Siglec-2 peut moduler les réponses allergiques et inflammatoires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés à Siglec-2 ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées peuvent apparaître en raison d'une inflammation liée à Siglec-2."
}
},
{
"@type": "Question",
"name": "Comment prévenir les dysfonctionnements de Siglec-2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un mode de vie sain et une bonne hygiène peut aider à prévenir les dysfonctionnements."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle Siglec-2 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en nutriments peut soutenir la fonction de Siglec-2."
}
},
{
"@type": "Question",
"name": "Le stress affecte-t-il Siglec-2 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut altérer la fonction immunitaire, y compris celle de Siglec-2."
}
},
{
"@type": "Question",
"name": "Les vaccinations aident-elles Siglec-2 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations peuvent renforcer la réponse immunitaire associée à Siglec-2."
}
},
{
"@type": "Question",
"name": "Y a-t-il des exercices bénéfiques pour Siglec-2 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer la fonction immunitaire et celle de Siglec-2."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent Siglec-2 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies biologiques et des anticorps monoclonaux peuvent cibler Siglec-2."
}
},
{
"@type": "Question",
"name": "Les anti-inflammatoires aident-ils avec Siglec-2 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les anti-inflammatoires peuvent réduire l'inflammation associée à Siglec-2."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux pour Siglec-2 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des essais cliniques évaluent des traitements ciblant Siglec-2 pour diverses maladies."
}
},
{
"@type": "Question",
"name": "Comment la thérapie génique peut-elle aider Siglec-2 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique pourrait corriger les dysfonctionnements liés à Siglec-2."
}
},
{
"@type": "Question",
"name": "Les probiotiques peuvent-ils influencer Siglec-2 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains probiotiques peuvent moduler l'expression de Siglec-2 et l'immunité."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec Siglec-2 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections graves et des maladies auto-immunes peuvent être des complications."
}
},
{
"@type": "Question",
"name": "Siglec-2 est-il lié à des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des altérations de Siglec-2 peuvent être associées à certains types de cancers."
}
},
{
"@type": "Question",
"name": "Les maladies cardiovasculaires sont-elles liées à Siglec-2 ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une inflammation chronique liée à Siglec-2 peut augmenter le risque cardiovasculaire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques neurologiques associés à Siglec-2 ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dysfonctionnements de Siglec-2 peuvent être impliqués dans des maladies neurologiques."
}
},
{
"@type": "Question",
"name": "Comment les complications de Siglec-2 affectent-elles la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent entraîner des limitations physiques et des problèmes de santé mentale."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque influencent Siglec-2 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge, les maladies chroniques et le mode de vie peuvent influencer la fonction de Siglec-2."
}
},
{
"@type": "Question",
"name": "Le tabagisme affecte-t-il Siglec-2 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut altérer la fonction immunitaire, y compris celle de Siglec-2."
}
},
{
"@type": "Question",
"name": "L'obésité est-elle un facteur de risque pour Siglec-2 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité peut provoquer une inflammation chronique affectant Siglec-2."
}
},
{
"@type": "Question",
"name": "Le diabète influence-t-il Siglec-2 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diabète peut altérer la réponse immunitaire et la fonction de Siglec-2."
}
},
{
"@type": "Question",
"name": "Le manque de sommeil affecte-t-il Siglec-2 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un sommeil insuffisant peut nuire à la fonction immunitaire, y compris celle de Siglec-2."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 20/02/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Biocience and Biotechnology Center, Nagoya University, Nagoya, 464-8601, Japan.
Department of Bioagricultural Sciences, Nagoya University, Nagoya, 464-8601, Japan.
Publications dans "Lectine-2 de type Ig liant l'acide sialique" :
3 publications dans cette catégorie
Affiliations :
Biocience and Biotechnology Center, Nagoya University, Nagoya, 464-8601, Japan. chi@agr.nagoya-u.ac.jp.
Department of Bioagricultural Sciences, Nagoya University, Nagoya, 464-8601, Japan. chi@agr.nagoya-u.ac.jp.
Publications dans "Lectine-2 de type Ig liant l'acide sialique" :
2 publications dans cette catégorie
Affiliations :
Institute for Glycomics, Griffith University, Gold Coast, Queensland, Australia.
Publications dans "Lectine-2 de type Ig liant l'acide sialique" :
2 publications dans cette catégorie
Affiliations :
Muping Coastal Environment Research Station, Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai, 264003, PR China; Center for Ocean Mega-science, Chinese Academy of Sciences, Qingdao, Shandong, 266071, PR China. Electronic address: dlyang@yic.ac.cn.
Publications dans "Lectine-2 de type Ig liant l'acide sialique" :
2 publications dans cette catégorie
Affiliations :
Division of Cell Recognition Study, Institute of Molecular Biomembrane and Glycobiology, Tohoku Medical and Pharmaceutical University.
Publications dans "Lectine-2 de type Ig liant l'acide sialique" :
2 publications dans cette catégorie
Affiliations :
Allakos, Inc, San Carlos, Calif.
Publications dans "Lectine-2 de type Ig liant l'acide sialique" :
2 publications dans cette catégorie
Affiliations :
Allakos, Inc, San Carlos, Calif.
Publications dans "Lectine-2 de type Ig liant l'acide sialique" :
2 publications dans cette catégorie
Affiliations :
Allakos, Inc, San Carlos, Calif.
Publications dans "Lectine-2 de type Ig liant l'acide sialique" :
2 publications dans cette catégorie
Affiliations :
Allakos, Inc, San Carlos, Calif.
Publications dans "Lectine-2 de type Ig liant l'acide sialique" :
2 publications dans cette catégorie
Affiliations :
Department of Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
Complex Carbohydrate Research Center, University of Georgia, Athens, GA, USA.
Department of Chemistry, University of Georgia, Athens, GA, USA.
Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, the Netherlands.
Publications dans "Lectine-2 de type Ig liant l'acide sialique" :
2 publications dans cette catégorie
Affiliations :
Department of Biomedical Sciences, Faculty of Health and Society, Malmö University, Malmö SE-20506, Sweden.
Publications dans "Lectine-2 de type Ig liant l'acide sialique" :
2 publications dans cette catégorie
Affiliations :
Department of Biomedical Sciences, Faculty of Health and Society, Malmö University, Malmö SE-20506, Sweden.
Publications dans "Lectine-2 de type Ig liant l'acide sialique" :
2 publications dans cette catégorie
Affiliations :
Department of Biomedical Sciences, Faculty of Health and Society, Malmö University, Malmö SE-20506, Sweden.
Publications dans "Lectine-2 de type Ig liant l'acide sialique" :
2 publications dans cette catégorie
Affiliations :
Interfaculty Institute of Biochemistry, University of Tuebingen, 72076 Tuebingen, Baden-Wuerttemberg, Germany. thilo.stehle@uni-tuebingen.de.
Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. thilo.stehle@uni-tuebingen.de.
Publications dans "Lectine-2 de type Ig liant l'acide sialique" :
2 publications dans cette catégorie
Affiliations :
Biocience and Biotechnology Center, Nagoya University, Nagoya, 464-8601, Japan.
Department of Bioagricultural Sciences, Nagoya University, Nagoya, 464-8601, Japan.
Publications dans "Lectine-2 de type Ig liant l'acide sialique" :
2 publications dans cette catégorie
Affiliations :
Department of Chemical Science and Engineering, School of Materials and Chemical Technology, Tokyo Institute of Technology, 2-12-1-H-101, Ookayama, Meguro, Tokyo, 152-8552, Japan.
Publications dans "Lectine-2 de type Ig liant l'acide sialique" :
2 publications dans cette catégorie
Affiliations :
Section of Virology, Division of Infectious Diseases & Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, The Netherlands.
Publications dans "Lectine-2 de type Ig liant l'acide sialique" :
2 publications dans cette catégorie
Affiliations :
Section of Virology, Division of Infectious Diseases & Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, The Netherlands.
Publications dans "Lectine-2 de type Ig liant l'acide sialique" :
2 publications dans cette catégorie
Affiliations :
Section of Virology, Division of Infectious Diseases & Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, The Netherlands.
Publications dans "Lectine-2 de type Ig liant l'acide sialique" :
2 publications dans cette catégorie
Affiliations :
Section of Virology, Division of Infectious Diseases & Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, The Netherlands.
Publications dans "Lectine-2 de type Ig liant l'acide sialique" :
Delivery time factor (DTF) is a new parameter introduced by the RayStation treatment planning system for tomotherapy treatment planning. This study investigated the effects of this factor on various t...
To clarify the characteristics of intraocular lens (IOL) dislocation requiring IOL suture or intraocular scleral fixation....
This retrospective consecutive case series included 21 eyes (21 patients) who required sutured or sutureless intrascleral IOL fixation following IOL extraction owing to IOL dislocation at the outpatie...
We included 21 eyes of 21 patients who required IOL suture or intrascleral fixation for IOL dislocation at our clinic from January to December 2019 were included. The most common background disease wa...
In this study, all 21 cases represented late IOL dislocations occurring after 3 months postoperatively. Among these late IOL dislocation cases, IOL dislocation occurred in a short-medium period of tim...
Large-scale and multidimensional spatiotemporal data sets are becoming ubiquitous in many real-world applications such as monitoring urban traffic and air quality. Making predictions on these time ser...
Postmeningitis deafness appears in 0-11% of the meningitis cases. Cochlear ossification can develop in these patients, which may make the hearing rehabilitation impossible with cochlear implantation. ...
The aim of this study was to examine the time factor between the appearance of deafness and the first examination in a cochlear implant centre, the possibilities and effectivity of hearing rehabilitat...
In our tertial referral centre, postmeningitis deafened patients were examined between 2014 and 2022 retrospectively. Hearing results, imaging, possibilities of rehabilitation, complications of cochle...
8 patients (3 children, 5 adults) were investigated. The time between the start of deafness and the first appearance varied between 3 weeks to 9 years. Bilateral profound hearing loss was measured in ...
The rehabilitation of severe hearing loss caused by meningitis can present many challenges to clinicians. A critical point in the care is the urgent referral of patients to a cochlear implantation cen...
It is recommended to develop a new protocol with the involvement of allied professions to clear patient pathways for an effective treatment strategy. Orv Hetil. 2023; 164(19): 729-738....
The duty factor (reflecting the ratio of stance to flight time) is an important variable related to running performance, economy, and injury risk. According to the dual-axis model, the duty factor and...
Can people modulate their duty factor based on verbal instructions to change either their stance or flight time without changing their cadence? And, if so, which instruction is most effective?...
Twelve participants ran on an instrumented treadmill and completed four training blocks starting with a baseline trial and ending with a performance trial in which they followed verbal instructions to...
The duty factor changed in intended directions with verbal instructions to increase and decrease the stance and flight time (18.04 ≤ BF...
Runners can change their duty factor through verbal instructions pertaining to stance or flight time, without clear concomitant effects on cadence. Running styles can thus be altered with verbal instr...
Cholecystectomy is one of the most frequently performed surgeries in Germany and is performed as a treatment of acute cholecystitis (guideline S3 IIIB.8) and after endoscopic retrograde cholangiopancr...
Methodologically, a retrospective analysis based on routine billing data from 84 Helios Group hospitals from 2016 and 2022, with a total of 45 393 included cases, was applied. The guideline adherence ...
Results show the guideline updates led to a statistically significant increase in the proportion of cholecystectomy performed in a timely manner (guideline S3 IIIB.8: increase from 43% to 49%, p<0.001...
As possible reasons for non-adherence, medical factors such as advanced age, multimorbidity and frailty could be identified. Analyses of structural factors revealed that hospitals in very rural region...
In this paper, two distributed finite-time neurodynamic algorithms are proposed to collaboratively manage the charging scheme of electric vehicles (EVs) in the microgrid scenario. First, the upper lev...
Rotator cuff pathology in competitive athletes is common and may produce chronic symptoms and joint disability, impairing sports participation and leading to premature retirement. Athletes are a high-...
To investigate the time-dependent effects of traditional risk factors on functional disability in all-cause mortality post-stroke, we evaluated data from a long-term stroke cohort. Baseline cerebrovas...
Financial management and decision-making of universities play an essential role in their development. Predicting fund revenue and expenditure of universities can provide a necessary basis for funds ri...